158 related articles for article (PubMed ID: 38142057)
21. [Malignant pleural mesothelioma: 2013 state of the art].
Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
[TBL] [Abstract][Full Text] [Related]
22. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
25. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
26. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Hassan R; Morrow B; Thomas A; Walsh T; Lee MK; Gulsuner S; Gadiraju M; Panou V; Gao S; Mian I; Khan J; Raffeld M; Patel S; Xi L; Wei JS; Hesdorffer M; Zhang J; Calzone K; Desai A; Padiernos E; Alewine C; Schrump DS; Steinberg SM; Kindler HL; King MC; Churpek JE
Proc Natl Acad Sci U S A; 2019 Apr; 116(18):9008-9013. PubMed ID: 30975761
[TBL] [Abstract][Full Text] [Related]
27. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
28. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
29. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Louw A; Panou V; Szejniuk WM; Meristoudis C; Chai SM; van Vliet C; Lee YCG; Dick IM; Firth T; Lynggaard LA; Asghari AB; Vyberg M; Hansen J; Creaney J; Røe OD
J Thorac Oncol; 2022 Jul; 17(7):921-930. PubMed ID: 35489694
[TBL] [Abstract][Full Text] [Related]
30. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature.
Symes E; Tjota M; Cody B; Kindler H; Mitchell O; Witmer H; Turaga K; Mueller J; Krausz T; Husain AN; Li H
Histopathology; 2024 Feb; 84(3):492-506. PubMed ID: 38084880
[TBL] [Abstract][Full Text] [Related]
31. Integrated Histogenetic Analysis Reveals
Bochtler T; Endris V; Reiling A; Leichsenring J; Schweiger MR; Klein S; Stögbauer F; Goeppert B; Schirmacher P; Krämer A; Stenzinger A
J Natl Compr Canc Netw; 2018 Jun; 16(6):677-682. PubMed ID: 29891518
[TBL] [Abstract][Full Text] [Related]
32. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
33. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
Yin W; Zheng G; Yang K; Song H; Liang Y
World J Surg Oncol; 2018 Mar; 16(1):44. PubMed ID: 29506546
[TBL] [Abstract][Full Text] [Related]
34. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Forde PM; Anagnostou V; Sun Z; Dahlberg SE; Kindler HL; Niknafs N; Purcell T; Santana-Davila R; Dudek AZ; Borghaei H; Lanis M; Belcaid Z; Smith KN; Balan A; White JR; Cherry C; Ashok Sivakumar IK; Shao XM; Chan HY; Singh D; Thapa S; Illei PB; Pardoll DM; Karchin R; Velculescu VE; Brahmer JR; Ramalingam SS
Nat Med; 2021 Nov; 27(11):1910-1920. PubMed ID: 34750557
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
36. Tumours associated with BAP1 mutations.
Murali R; Wiesner T; Scolyer RA
Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
[TBL] [Abstract][Full Text] [Related]
37. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
38.
Guazzelli A; Meysami P; Bakker E; Demonacos C; Giordano A; Krstic-Demonacos M; Mutti L
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669483
[TBL] [Abstract][Full Text] [Related]
39. BAP1 protein is a progression factor in malignant pleural mesothelioma.
Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]